Cargando…
Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC) patients. Thus, there is an urgent need to develo...
Autores principales: | Fu, Yuyin, Peng, Yujia, Zhao, Shengyan, Mou, Jun, Zeng, Lishi, Jiang, Xiaohua, Yang, Chengli, Huang, Cheng, Li, Yuyan, Lu, Yin, Wu, Mengdan, Yang, Yanfang, Kong, Ting, Lai, Qinhuai, Wu, Yangping, Yao, Yuqin, Wang, Yuxi, Gou, Lantu, Yang, Jinliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298272/ https://www.ncbi.nlm.nih.gov/pubmed/34307367 http://dx.doi.org/10.3389/fcell.2021.689727 |
Ejemplares similares
-
Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma
por: Tao, Yiran, et al.
Publicado: (2019) -
Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017) -
Effective antitumor activity of 5T4‐specific CAR‐T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo
por: Guo, Cuiyu, et al.
Publicado: (2020) -
Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models
por: Yu, Lin, et al.
Publicado: (2017) -
Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling
por: Chen, Xiangzheng, et al.
Publicado: (2016)